CareDx Q1 revenue $77.3M (-3% YoY); withdraws 2023 guidance on billing article uncertainty

CareDx, Inc.

2023-Q1 EPS reported -$0.44 revenue$77,262,000

Record test volumes 49,900 (AlloMap/AlloSure), up 17% YoY; testing services revenue $61.8M.
GAAP net loss $23.7M ($0.44 loss per share); adjusted EBITDA loss $6.4M.
Patient & Digital Solutions revenue $8.6M, up 39% YoY; cash $285.9M, no debt.
Withdrew 2023 revenue guidance due to MolDX Billing Article revisions in March and May 2023.
Delayed submission of ~$8.9M in AlloSure Kidney Medicare tests from Q1 to Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CareDx, Inc. reported the first quarter ended March 31, 2023 results: revenue $77.3 million, net income net loss of $23.7 million, EPS basic and diluted net loss per share of $0.44.

Period: the first quarter ended March 31, 2023
Revenue: $77.3 million
Net income: net loss of $23.7 million
EPS: basic and diluted net loss per share of $0.44
Result: reported results

Exact text from the filing

test results for AlloMap® and AlloSure® of approximately 49,900 tests, growing year-over-year by 17%, and exceeding year-over-year market growth of 10%. • Reported revenue of $77.3 million, a decrease of 3% year-over year. This excludes approximately $8.9 million in revenue associated with approximately 3,200 AlloSure Kidney Medicare tests that the Company did not

View on SEC.gov

Browse all earnings releases →

CareDx, Inc. filing history →

Source: SEC EDGAR

accession 0001217234-23-000094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.